FOURKITES
16.11.2023 10:52:28 CET | Business Wire | Press release
FourKites today announces new additions to its senior leadership team to maximise customer value. Technology industry veteran Sean Fallon returns to FourKites as Chief Strategy Officer to drive strategy and support continued growth. Chief Product Officer Priya Rajagopalan takes on an expanded role that closely aligns customer operations and product development teams to maximise customer value. In addition, Mike DeAngelis (based in Denmark) joins as Head of International Solutions with a focus on ocean, having formerly worked at Maersk, WiseTech Global and project44.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116700075/en/
FourKites appoints new executives to accelerate customer-driven innovation (Graphic: Business Wire)
FourKites’ 1,200 customers represent some of the largest and most complex supply chains in the world, and the platform touches over 50% of the Fortune 500. As global supply chains continue to grow in complexity, customers’ need for visibility beyond transportation has accelerated, and now requires end-to-end solutions that provide visibility into inventory, yards, warehouses, stores and beyond.
Gartner reflected this challenge in its 2023 Critical Capabilities for Real-Time Transportation Visibility Platforms report, and recognised FourKites as the top-scoring solution for the world’s most complex supply chains, specifically calling out the company’s “modal coverage and extended capabilities.” In addition, FourKites continues to garner accolades for its industry-leading innovation, most recently in FreightWaves’ FreightTech 25, which recognises the most innovative and disruptive companies in the freight technology sector. FourKites is the only visibility provider named to this year’s list — and together with Amazon Freight and J.B. Hunt, it is one of only three companies to appear on every list since 2018.
To support FourKites’ aggressive innovation agenda to provide maximum visibility for its customers, FourKites has expanded the scope of Chief Product Officer Priya Rajagopalan’s role to encompass customer operations, product and R&D. A seasoned business leader with over two decades of experience in product management, marketing and strategy, Rajagopalan has led FourKites’ Product team since 2016. She helped to build FourKites’ culture of customer-driven innovation, as many of FourKites’ platform capabilities have been developed in close collaboration with customers such as Land O’Lakes, Coca-Cola, Kimberly-Clark, Walmart Canada and others.
In addition, FourKites announced the return of Sean Fallon as Chief Strategy Officer to manage operational execution. Fallon is a seasoned technology executive and advisor, with extensive experience in private equity and venture-backed companies. With a focus on advancing enterprise software and SaaS businesses, he has led businesses through strategic liquidity events and M&A, including the sale of BigMachines to Oracle in 2013. Fallon served as President at FourKites from 2017 to 2021.
FourKites has also appointed Mike DeAngelis as Head of Ocean, where he will drive strategy and innovation around FourKites’ ocean solutions. A proven industry leader, DeAngelis served as General Manager and Head of Product Management at Maersk, Senior VP of global carrier strategy at WiseTech Global, and was most recently Senior Director of Growth, Ocean, at project44.
“We are excited to announce these appointments at a time when customers are looking for more opportunities for digitisation than ever before,” said Mathew Elenjickal, FourKites founder and CEO. “These additions bring a tight connection between the voice of the customer and our high-velocity R&D team, which will yield accelerated opportunities for innovation and customer value.”
These appointments come at a time of continued company growth as customers increasingly seek solutions beyond transportation visibility. Over the last year, FourKites has achieved a 28% increase in customers; 37% growth in its carrier network; and nearly 30% growth in shipment volume, across more than 220 countries and territories. The company sets the pace of innovation in the supply chain visibility market — most recently with Inbound Visibility, Appointment Manager, Fin AI (FourKites Intelligence Network) and My Workspace — as FourKites continues to expand its capabilities beyond transportation to provide customers with real-time insights that expedite decision-making throughout their end-to-end supply chain operations.
About FourKites
Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116700075/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
